Despite these insights, therapeutic options targeting these mutations remain elusive, and patients with SMARCA4-deficient NSCLC typically exhibit poorer prognostic outcomes and shorter overall survival compared to their wild-type counterparts. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.